Adeno-Associated Virus-Mediated Gene Transfer to Nonhuman Primate Liver Can Elicit Destructive Transgene-Specific T Cell Responses
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Gene transfer to murine liver with vectors based on novel adeno-associated virus (AAV) serotypes is efficient, stable, and safe even in the setting of antigenic transgene products. We undertook a study in cynomolgus macaques to evaluate the relevance of these findings to primates. The vectors were based on AAV serotype 7 and expressed green fluorescence protein (GFP) from the cytomegalovirus enhanced beta-actin promoter in both single-stranded and self-complementary genomes. Transduction efficiencies from the single-stranded vectors were similar to those observed in mice, although there was no advantage in primates with the self-complementary vectors. Primates elicited vibrant cytotoxic T cell responses to GFP that correlated with hepatitis and loss of transgene expression. There was no evidence of T cell activation in response to the AAV capsid. These studies indicate that under some conditions primates may activate more robust T cell responses to transgene products than is observed in mice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
McCarty, D., Monahan, P., & Samulski, R. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301514 · Cited by 735 · cited 1×
“…improving AAV transduction effi-ciency is to use genomes that are capable of self-annealing to overcome the need to replicate the input genome (called self-complementary [sc] vectors) (Hirata and Russell, 2000; McCarty et al. , 2001; Wang et al. , 2003; Gao et al. , 2006b; Nathwani et al. , 2006).”
New recombinant serotypes of AAV vectors
Gao, G., Vandenberghe, L., & Wilson, J. (2005) · Current Gene Therapy · doi:10.2174/1566523054065057 · Cited by 487
Self-citationHeparin binding directs activation of T cells against adeno-associated virus serotype 2 capsid
Vandenberghe, L. H., Wang, L., Somanathan, S., Zhi, Y., Figueredo, J., Calcedo, R., Sanmiguel, J., Desai, R. A., Chen, C. S., Johnston, J., et al. (2006) · Nature Medicine · doi:10.1038/nm1445 · Cited by 208 · cited 1×
“…to primates, including AAV serotypes 7 and 8, which have low sero-prevalence in humans, diminished activation of capsid T cells, and improved transduction efficiency of hepatocytes in most preclinical models (Gao et al. , 2002; Vandenberghe et al. , 2006; Wang et al. , 2007; Calcedo et al. , 2009).”
Self-citationDesign and Packaging of Adeno-Associated Virus Gene Targeting Vectors
Hirata, R. K., & Russell, D. W. (2000) · Journal of Virology · doi:10.1128/jvi.74.10.4612-4620.2000 · Cited by 133 · cited 2×
“…improving AAV transduction effi-ciency is to use genomes that are capable of self-annealing to overcome the need to replicate the input genome (called self-complementary [sc] vectors) (Hirata and Russell, 2000; McCarty et al. , 2001; Wang et al. , 2003; Gao et al. , 2006b; Nathwani et al. , 2006).”
Wang, L., Figueredo, J., Calcedo, R., Lin, J., & Wilson, J. M. (2007) · Human Gene Therapy · doi:10.1089/hum.2007.001 · Cited by 113 · cited 2×
“…limitations of these vectors emerged, such as poor transduction efficiency, activation of T cells against the capsid, and substantial quantities of preexisting neutralizing antibodies in human populations (Grimm and Kay, 2003; Van-denberghe et al. , 2006; Wang et al. , 2007; Calcedo et al. , 2009).”
Self-citation
Cited by
Immune responses to AAV vectors: overcoming barriers to successful gene therapy
Mingozzi, F., & High, K. A. (2013) · Blood · doi:10.1182/blood-2013-01-306647 · Cited by 955
“39,79 Recent studies suggest differences in frequencies and subset distributions of AAV capsid-speci fi c CD4 1 and CD8 1 T cells in humans and NHPs, 80 perhaps related to differences in the AAV life cycle in the 2 species.”
AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer
Costa Verdera, H., Kuranda, K., & Mingozzi, F. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.12.010 · Cited by 641
Goertsen, D., Flytzanis, N. C., Goeden, N., Chuapoco, M. R., Cummins, A., Chen, Y., Fan, Y., Zhang, Q., Sharma, J., Duan, Y., et al. (2022) · Nature Neuroscience · doi:10.1038/s41593-021-00969-4 · Cited by 420
Self-citationCpG-depleted adeno-associated virus vectors evade immune detection
Faust, S. M., Bell, P., Cutler, B. J., Ashley, S. N., Zhu, Y., Rabinowitz, J. E., & Wilson, J. M. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68205 · Cited by 254
Self-citationUnraveling the complex story of immune responses to AAV vectors trial after trial.
Vandamme, C., Adjali, O., & Mingozzi, F. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.150 · Cited by 234
Multifunctional CRISPR-Cas9 with Engineered Immunosilenced Human T Cell Epitopes
Ferdosi, S. R., Ewaisha, R., Moghadam, F., Krishna, S., Park, J. G., Ebrahimkhani, M. R., Kiani, S., & Anderson, K. S. (2019) · Nature Communications · doi:10.1038/s41467-019-09693-x · Cited by 204
Gray, S. J., Blake, B. L., Criswell, H. E., Nicolson, S. C., Samulski, R. J., & McCown, T. J. (2010) · Molecular Therapy · doi:10.1038/mt.2009.292 · Cited by 185
Adeno-associated viral vector-mediated immune responses: Understanding barriers to gene delivery
Nidetz, N. F., McGee, M. C., Tse, L. V., Li, C., Cong, L., Li, Y., & Huang, W. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107453 · Cited by 174
Hordeaux, J., Buza, E. L., Jeffrey, B., Song, C., Jahan, T., Yuan, Y., Zhu, Y., Bell, P., Li, M., Chichester, J. A., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aba9188 · Cited by 174
Self-citationQiao, C., Yuan, Z., Li, J., He, B., Zheng, H., Mayer, C., Li, J., & Xiao, X. (2011) · Gene Therapy · doi:10.1038/gt.2010.157 · Cited by 163
The Pleiotropic Effects of Natural AAV Infections on Liver-directed Gene Transfer in Macaques
Wang, L., Calcedo, R., Wang, H., Bell, P., Grant, R., Vandenberghe, L. H., Sanmiguel, J., Morizono, H., Batshaw, M. L., & Wilson, J. M. (2010) · Molecular Therapy · doi:10.1038/mt.2009.245 · Cited by 130
Self-citationHordeaux, J., Hinderer, C., Goode, T., Katz, N., Buza, E. L., Bell, P., Calcedo, R., Richman, L. K., & Wilson, J. M. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.06.003 · Cited by 105
Self-citationHordeaux, J., Hinderer, C., Goode, T., Buza, E. L., Bell, P., Calcedo, R., Richman, L. K., & Wilson, J. M. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.06.004 · Cited by 81
Self-citationCalcedo, R., Somanathan, S., Qin, Q., Betts, M. R., Rech, A. J., Vonderheide, R. H., Mueller, C., Flotte, T. R., & Wilson, J. M. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1617726114 · Cited by 79
Self-citationHoffman, B. E., Martino, A. T., Sack, B. K., Cao, O., Liao, G., Terhorst, C., & Herzog, R. W. (2011) · Molecular Therapy · doi:10.1038/mt.2011.33 · Cited by 72
Greig, J. A., Limberis, M. P., Bell, P., Chen, S.-J., Calcedo, R., Rader, D. J., & Wilson, J. M. (2017) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2017.014 · Cited by 56
Self-citationIn Situ Detection of Adeno-associated Viral Vector Genomes with SABER-FISH
Wang, S. K., Lapan, S. W., Hong, C. M., Krause, T. B., & Cepko, C. L. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2020.10.003 · Cited by 36
Boyd, R. F., Boye, S. L., Conlon, T. J., Erger, K. E., Sledge, D. G., Langohr, I. M., Hauswirth, W. W., Komáromy, A. M., Boye, S. E., Petersen-Jones, S. M., et al. (2016) · Gene Therapy · doi:10.1038/gt.2016.31 · Cited by 37
Hordeaux, J., Ramezani, A., Tuske, S., Mehta, N., Song, C., Lynch, A., Lupino, K., Chichester, J. A., Buza, E. L., Dyer, C., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1094279 · Cited by 23
Self-citationIdentification of the murine AAVrh32.33 capsid-specific CD8+ T cell epitopes
Mays, L. E., & Wilson, J. M. (2009) · The Journal of Gene Medicine · doi:10.1002/jgm.1402 · Cited by 13
Self-citationGene-sized DNA insertion at genomic safe harbors in human cells using a site-directed transposase
(2025) · doi:10.1093/nar/gkaf1316 · Cited by 2
Metadata
- Authors
- Gao, G., Wang, Q., Calcedo, R., Mays, L., Bell, P., Wang, L., Vandenberghe, L. H., Grant, R., Sanmiguel, J., Furth, E. E., & Wilson, J. M.
- Venue
- Human Gene Therapy
- Publisher
- SAGE Publications
- Published
- 2009-09
- Volume
- 20
- Issue
- 9
- Pages
- 930-942
- ISSN
- 1043-0342 (ISSN-L)
- 1557-7422
- OpenAlex
- W2023133801
- Cited by
- 103
- References
- 6
- FWCI
- 4.63
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.